Patent US4785842A successfully refreshed from Google Patents.
Patent US1308425A successfully refreshed from Google Patents.
Patent US3881015A successfully refreshed from Google Patents.
US3881015A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions and methods of inhibiting histamine activity with isothiourea compounds
Assignee: Smith Kline & French Laboratories Ltd
•
Filing: 1974-06-13
•
Granted: 1975-04-29
•
Expires: 1994-06-13
Abstract
Abstract Pharmaceutical compositions and methods of inhibiting histamine activity with N-(heterocyclic-alkyl)isothioureas.
Inventors
- 👤 James Whyte Black
- 👤 Graham John Durant
- 👤 John Colin Emmett
- 👤 Charon Robin Ganellin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 11:45
CPC Classifications
C; C07; C07D; C07D277/00; C07D277/02; C07D277/20; C07D277/22; C07D277/28; C07D209/00; C07D209/02; C07D209/44; C07D209/48; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/36; C07D213/40; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/04; C07D233/20; C07D233/24; C07D233/26; C07D233/54; C07D233/64; C07D249/00; C07D249/02; C07D249/08
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
46 words
A PHARMACEUTICAL COMPOSITION TO INHIBIT H-2 HISTAMINE RECEPTORS, SAID H-2 HISTAMINE RECEPTORS BEING THOSE HISTAMINE RECEPTORS WHICH ARE NOT INHIBITED BY MEPYRAMINE BUT ARE INHIBITED BY BURIMAMIDE, COMPRISING A, PHARMACEUTICAL CARRIER AND, IN AN EFFECTIVE AMOUNT TO INHIBIT SAID RECEPTORS, AN ISOTHIOUREA COMPOUND OF THE FORMULA:
Claim 2
Dependent Claim
46 words
A PHARMACEUTICAL COMPOSITION TO INHIBIT H-2 HISTAMINE RECEPTORS, SAID H-2 HISTAMINE RECEPTORS BEING THOSE HISTAMINE RECEPTORS WHICH ARE NOT INHIBITED BY MEPYRAMINE BUT ARE INHIBITED BY BURIMAMIDE, COMPRISING A, PHARMACEUTICAL CARRIER AND, IN AN EFFECTIVE AMOUNT TO INHIBIT SAID RECEPTORS, AN ISOTHIOUREA COMPOUND OF THE FORMULA:
Claim 3
Dependent Claim
25 words
A pharmaceutical composition according to claim 1 in which A is such that it forms with the carbon and nitrogen atoms shown a 4(5)-imidazolyl ring.
Claim 4
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 in which the isothiourea compound is S-ethyl-N-(3-(4(5)-imidazolyl)propyl)isothiourea dihydriodide.
Claim 5
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 in which the isothiourea compound is S-ethyl-N-(3-(4(5)-imidazolyl)propyl)isothiouronium sulphate.
Claim 6
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 in which the isothiourea compound is S-(2-phenethyl)-N-(3-(4(5)-imidazolyl)propyl)isothiourea dihydrobromide.
Claim 7
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 in which the isothiourea compound is S-propargyl-N-(3-(4(5)-imidazolyl)propyl)isothiourea dihydrobromide.
Claim 8
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 in which the isothiourea compound is S-methyl-N-(4-(4(5)-imidazolyl)butyl)isothiouronium sulphate.
Claim 9
Independent Claim
50 words
A method of inhibiting H-2 histamine receptors, said H-2 histamine receptors being those histamine receptors which are not inhibited by mepyramine but are inhibited by burimamide, which comprises administering to an animal requiring said inhibition in an amount sufficient to inhibit H-2 histamine receptors an isothiourea compounds of the formula:
Claim 10
Independent Claim
50 words
A method of inhibiting H-2 histamine receptors, said H-2 histamine receptors being those histamine receptors which are not inhibited by mepyramine but are inhibited by burimamide, which comprises administering to an animal requiring said inhibition in an amount sufficient to inhibit H-2 histamine receptors an isothiourea compounds of the formula:
Claim 11
Dependent Claim
24 words
A method according to claim 8 in which A is such that is forms with the carbon and nitrogen atoms shown a 4(5)-imidazolyl ring.
Claim 12
Independent Claim
37 words
A method of inhibiting gastirc acid secretion which comprises administering internally to an animal in need of inhibition of gastric acid secretion in an amount sufficient to inhibit gastric acid secretion an isothiourea compound of the formula:
Claim 13
Independent Claim
37 words
A method of inhibiting gastirc acid secretion which comprises administering internally to an animal in need of inhibition of gastric acid secretion in an amount sufficient to inhibit gastric acid secretion an isothiourea compound of the formula:
Claim 14
Independent Claim
31 words
A method of producing anti-inflammatory activity which comprises administering to an animal in need of said activity in an amount sufficient to produce said activity an isothiourea compound of the formula:
Claim 15
Independent Claim
31 words
A method of producing anti-inflammatory activity which comprises administering to an animal in need of said activity in an amount sufficient to produce said activity an isothiourea compound of the formula:
References Cited (Backward Citations)
US3558640A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-04-28 | 1978-10-28 | 1979-04-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-04-28 | 1982-10-28 | 1983-04-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-04-28 | 1986-10-28 | 1987-04-29 | $7700.00 | Window Closed / Lapsed |